CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions and diseases. Learn more at https://cormedix.com/
 DefenCath (taurolidine and heparin) is approved by the US Food and Drug Administration to reduce catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure receiving chronic hemodialysis from a central venous catheter (HD-CVC) |